Related Experiment Video
Updated: Jun 21, 2025
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7.2K
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study
Lisa A Beck1, Robert Bissonnette2, Mette Deleuran3
1Department of Dermatology, University of Rochester Medical Center, Rochester, New York.
JAMA Dermatology
|July 10, 2024
Summary
Long-term dupilumab treatment demonstrated sustained safety and efficacy for adults with moderate to severe atopic dermatitis (AD). Continuous use up to 5 years showed significant improvements in skin clearance and reduced disease severity.
Area of Science:
- Dermatology
- Immunology
- Clinical Trials
Background:
- Moderate to severe atopic dermatitis (AD) is a chronic inflammatory skin condition requiring long-term systemic management.
- Continuous long-term safety and efficacy data are crucial for evaluating treatment options.
Purpose of the Study:
- To assess the long-term safety and efficacy of dupilumab in adult patients with moderate to severe AD over a 5-year period.
Main Methods:
- A 5-year open-label extension study (LIBERTY AD) enrolled adults with moderate to severe AD previously treated with dupilumab.
- Patients received subcutaneous dupilumab, with dosage adjustments over time.
- Primary endpoints included treatment-emergent adverse events (TEAEs); secondary endpoints assessed skin clearance (IGA 0-1) and Eczema Area and Severity Index (EASI) improvement.
Main Results:
- 2677 patients were enrolled; 334 (12.5%) completed 5 years of treatment.
- Exposure-adjusted rates of TEAEs remained stable or declined; common TEAEs included nasopharyngitis and conjunctivitis.
- At week 260, 67.5% achieved an Investigator's Global Assessment (IGA) score of 0 or 1, and 88.9% achieved ≥75% EASI improvement.
Conclusions:
- Continuous long-term dupilumab treatment up to 5 years shows sustained safety and efficacy in adults with moderate to severe AD.
- The findings support dupilumab as a viable long-term therapeutic option for this patient population.
